ICU Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
SeaStar Medical Holding Corp (ICU) is not a strong buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. Despite promising news on its QUELIMMUNE therapy and significant revenue growth, the company faces financial challenges, including a substantial net income loss and declining EPS. Technical indicators are neutral to bearish, and there are no strong trading signals or notable trading trends to support an immediate buy decision.
The MACD is slightly positive but contracting, indicating weak momentum. RSI is neutral at 36.165, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Support levels are at 2.27 and 2.15, while resistance levels are at 2.66 and 2.78. The stock has a 70% chance of declining in the short term (-0.18% in the next day, -0.75% in the next week) but shows potential for a 14.56% increase in the next month.
The QUELIMMUNE therapy has shown strong survival rates and a favorable safety profile in critically ill pediatric patients. Adoption by prominent children's medical centers in the U.S. is a positive development. Revenue increased significantly by 169.12% YoY in Q3 2025.
Gross margin also decreased by -7.65% YoY. Technical indicators suggest bearish momentum, and there are no significant trading trends from hedge funds or insiders.
In Q3 2025, revenue increased by 169.12% YoY to $183,000, but net income dropped to -$3,472,000 (-22.47% YoY). EPS fell to -1.32 (-87.96% YoY), and gross margin declined to 92.35% (-7.65% YoY). The company is showing revenue growth but struggling with profitability.
No analyst rating or price target data provided.
